Table 1.
Baseline characteristics of allo-HSCT recipients and healthy controls
| Allo-HSCT* (n = 50) | Healthy controls (n = 39) | |
|---|---|---|
| Age at vaccination median, y (range) | 54 (29-78) | 60 (25-86) |
| Sex, female/male | 24/26 | 24/15 |
| Vaccine, Moderna/Pfizer-BioBTech | 18/32 | 2/37 |
| Days from dose 2 to sampling, median (range) | 27 (16-33) | 28 (14-147) |
| Months from transplantation, median (range) | 92 (7-340) | NA |
| Chronic GVHD (yes/no) | 18/32 | NA |
| Diagnosis (n) | ||
| Acute myeloid leukemia | 20 | NA |
| Acute lymphatic leukemia | 5 | NA |
| Chronic myeloid leukemia | 7 | NA |
| Chronic lymphatic leukemia | 3 | NA |
| Lymphoma | 2 | NA |
| Myelodysplastic syndrome | 7 | NA |
| Myelofibrosis | 2 | NA |
| Aplastic anemia | 2 | NA |
| Multiple myeloma | 1 | NA |
| Thalassemia | 1 | NA |
| Donor RD/URDhaplo | 15/34/1 | NA |
| Conditioning RIC/MAC | 25/25 | NA |
| Immunosuppressive therapy at time of first vaccination (n) | 9 | 0 |
| Corticosteroids | 7 | 0 |
| Ibrutinib | 2 | 0 |
| Ciclosporin | 1 | 0 |
| Imatinib | 2 | 0 |
MAC, myeloablative conditioning; NA, not applicable; RD, related donor; RIC, reduced intensity conditioning; URD, unrelated donor.
*
Allogeneic hematopoietic stem cell transplantation.